Spotlight on Oncology

Credits: 0.50 CME / CNE / CPE
Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part One
Matthew Rettig, MD
Rush University Medical Center

Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part One

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: April 16, 2018
Expires: April 15, 2019
30 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved in the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  • Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Understand the molecular and biochemical underpinnings of mCRPC.
  • Describe molecular biomarkers that predict for response to novel targeted therapies.

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
Los Angeles, CA

Dr. Rettig has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity:
Research Grant: Novartis
Member, Speakers Bureau: Janssen
Consultant: Janssen


Michaela Ryan, PhD
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Kimberly Lynch
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Beth-Anne M. Christopher MS, RN, CNL
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-053-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology Inc., Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Oncology Presentations

0.50 CME / CNE / CPE
AXIS
Managing Metastatic NSCLC: Strategies for Treatment Selection

Managing Metastatic NSCLC: Strategies for Treatment Selection

Start

Activity Details

Free CME/CPE/CNE
0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: June 11, 2018
Expires: June 10, 2019
30 minutes to complete

Provided By

Target Audience

This activity is intended for community oncologists, nurses, pharmacists, and other healthcare professionals who manage NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Summarize the indications, efficacy, and safety profiles of recently approved therapies for NSCLC, including EGFR and checkpoint inhibitors
  • Devise treatment selection and drug sequencing strategies that incorporate newer therapies for patients with metastatic NSCLC
  • Identify potential toxicities associated with therapies used for NSCLC

Activity Description

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the treatment of NSCLC so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices for their patients. AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on NSCLC.

Statement of Educational Need

The treatment of NSCLC has changed significantly as a result of the identification of clinically relevant biomarkers and the development of targeted therapies. Although patient outcomes have improved as a result of treatment advances, metastatic disease is still an important challenge. Knowledge and practice gaps can be seen in several aspects of the treatment of metastatic NSCLC, such as how to integrate new therapies into practice, manage toxicities associated with new therapies, and make best use of a shared decision-making approach to treatment.

Faculty

David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology
Professor of Medicine
Professor of Radiation Oncology and Molecular Radiation Sciences
The Johns Hopkins University School of Medicine
Baltimore, Maryland


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

David S. Ettinger, MD, FACP, FCCP, serves(d) as an advisor/consultant for:
BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Golden Biotechnology Corporation; and Guardant Health, Inc.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda-Gracie-King, MS; Jocelyn Timko, BS; Kristen Baileys, RN, MSN, CRNP, OCN; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD,hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-0000-18-017-H01-P

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
Rush University Medical Center
Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part Two

Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part Two

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: April 16, 2018
Expires: April 15, 2019
30 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved in the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  • Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Understand the molecular and biochemical underpinnings of mCRPC.
  • Describe molecular biomarkers that predict for response to novel targeted therapies.

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
Los Angeles, CA

Dr. Rettig has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity:
Research Grant: Novartis
Member, Speakers Bureau: Janssen
Consultant: Janssen


Michaela Ryan, PhD
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Kimberly Lynch
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Beth-Anne M. Christopher MS, RN, CNL
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-057-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology Inc., Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
Rush University Medical Center
Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part One

Evolving Treatment Paradigms in Advanced Prostate Cancer: Individualizing Treatment Strategies Based on Advancing Clinical Data—Part One

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: April 16, 2018
Expires: April 15, 2019
30 minutes to complete

Accredited By

Rush University Medical Center

Co-provided By

Target Audience

Healthcare providers who are involved in the treatment of patients with prostate cancer

Learning Objectives

After completing this program, participants should be able to:

  • Identify best practices for integrating current available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals.
  • Understand the molecular and biochemical underpinnings of mCRPC.
  • Describe molecular biomarkers that predict for response to novel targeted therapies.

Activity Description

The activity agenda has been designed to help clinicians understand best practice approaches to utilizing all the current therapies in advanced prostate cancer to ensure optimal patient outcomes.

Faculty

Matthew B. Rettig, MD
Medical Oncologist
Ronald Reagan UCLA Medical Center and VA Greater Los Angeles Healthcare System
Los Angeles, CA

Dr. Rettig has disclosed having financial arrangements or affiliations with the following commercial interest(s) whose products or services may be mentioned in this activity:
Research Grant: Novartis
Member, Speakers Bureau: Janssen
Consultant: Janssen


Michaela Ryan, PhD
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Kimberly Lynch
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Beth-Anne M. Christopher MS, RN, CNL
Has disclosed having no financial arrangements or affiliations with any commercial interests whose products or services may be mentioned in this activity.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing nursing education credit(s).

Rush University Medical Center designates this enduring activity for a maximum of 0.5 continuing education unit(s) in Pharmacy. UAN: JA0000275-0000-18-053-H01-P.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 75% or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation, Inc., a Pfizer company, Clovis Oncology Inc., Janssen Biotech Inc. administered by Janssen Scientific Affairs, LLC, and Tolmar Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CNE
AXIS
Oncology On-Que: Expert Answers to Common Questions for Optimizing Sarcoma Treatment

Oncology On-Que: Expert Answers to Common Questions for Optimizing Sarcoma Treatment

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hours for nurses
Released: March 6, 2018
Expires: March 5, 2019
15 minutes to complete

Provided By

Target Audience

This activity is intended for medical oncologists, surgical oncologists, radiation oncologists, orthopedic oncologists, pathologists, researchers, advanced practitioners, nurses, and other healthcare professionals who treat soft-tissue sarcomas.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Integrate dosing and administration recommendations for treatment with doxorubicin plus olaratumab
  • Use appropriate therapies for the treatment of soft-tissue sarcomas according to guideline recommendations
  • Identify appropriate treatments for uterine sarcoma
  • Recognize and manage adverse events in patients being treated for soft-tissue sarcomas
  • Assess advances in molecular testing in determining treatment approach
  • Evaluate emerging data for the use of immunotherapy in the treatment of soft-tissue sarcomas

Activity Description

Soft-tissue sarcomas (STS) comprise a heterogeneous group of rare diseases of mesenchymal origin. Its rarity (1% of adult malignancies) and diverse presentation (180+ classified subtypes) make STS a challenge to diagnose and treat. The standard of care involves a multimodal approach of radiation therapy, surgery, and chemotherapy; however, the 5-year survival rate for advanced/metastatic STS has remained approximately 16% for many years. Fortunately, there are multiple newly approved and emerging agents in late-stage clinical trials that may revolutionize the treatment of STS.

Because STS treatment is rapidly evolving, clinicians may not be up to date regarding the latest advances in the treatment of this disease, including available, newer, and emerging treatment options, making it challenging to provide state-of-the-art care to their patients.

AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. The topics outlined below feature a summary of the questions that were asked during a recent grand rounds series on sarcoma. This activity will review:

  • Dosing and administration of olaratumab
  • Treatments for uterine sarcoma
  • Adverse events and management
  • Choice of treatment/therapy
  • Optimal surveillance schedule for localized disease
  • The role of adjuvant chemotherapy
  • Molecular testing
  • The use of immunotherapy

Statement of Educational Need

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the treatment of sarcoma so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices for their patients.

Faculty

Richard F. Riedel, MD
Associate Professor with Tenure
Division of Medical Oncology
Associate Director, Clinical & Translational Research Duke Sarcoma Program
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina


Conflict of Interest Policy/Disclosure Statement

The faculty, Richard F. Riedel, MD, reported a financial interest/relationship or affiliation in the form of Consultant/Advisory boards, Eisai Inc., EMD Serono, Ignyta, Janssen Biotech, Inc., Lilly USA, Loxo Oncology; Contracted research, Aadi Bioscience, Inc., AROG Pharmaceuticals, Inc., Bayer Pharmaceuticals Corporation, Eisai Inc., Ignyta, Immune Design, Karyopharm Therapeutics, Lilly USA, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Plexxikon, TRACON Pharmaceuticals, Inc.; Ownership, Biotech Prosthetics & Orthotics of Durham (Spouse), Limbguard, LLC (Spouse).

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Continuing Education Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other related information.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE
Postgraduate Institute for Medicine
A System-Based Patient-Centered Approach to HER2-Positive Breast Cancer

A System-Based Patient-Centered Approach to HER2-Positive Breast Cancer

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit
0.5 ANCC contact hour
0.5 APRN contact hour
Released: February 20, 2018
Expires: February 20, 2019
0.5 hour to complete

Jointly Provided By

Target Audience

Oncology clinicians, including physicians, nurses, nurse practitioners, and physician assistants

Learning Objectives

After completing this educational activity, the participant will demonstrate the ability to:

  1. Routinely use ASCO/CAP13 guidelines to determine HER2 status that guide management and assist in evaluating risk
  2. Integrate evolving targeted treatment paradigms into clinical practice for patients with HER2-positive breast cancer, based on efficacy and safety
  3. Utilize evidence-based and guideline recommendations for neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive breast cancer
  4. Develop a strong patient-provider collaborative approach to managing patients with breast cancer that includes multidisciplinary management, patient education, engagement, and shared decision making

Activity Description

Breast cancer is expected to affect over 250,000 American women in 2017, making it the most common cancer in women.1 When the disease is confined to the breast and regional lymph nodes, it is frequently curable. However, metastatic disease is significantly more challenging to treat and accounts for the majority of the over 40,000 breast cancer associated deaths in the United States per year.1 Contributing to this treatment challenge are the estimated 18% to 20% of patients with invasive breast cancer who overexpress the human epidermal growth factor receptor 2 (HER2), which is associated with more aggressive disease and poorer prognosis, but a markedly better response to the combination of chemotherapy and targeted agents.2 Over the last 2 decades, a number of advances have been made for treating patients with HER2-positive breast cancer, which has significantly improved outcomes in both early- and late-stage disease. However, resistance to HER2-targeted therapies and understanding the mechanisms contributing to a less than optimal response continues to be a challenge. Newer therapies are being developed to meet this need that have the potential to shift the treatment paradigm for patients with HER2-positive breast cancer. For now, the appropriate use of treatment guidelines, incorporation of evolving targeted treatment paradigms, and the ability to engage the patient in the decision-making process around therapeutic options, are key to improving outcomes for patients with HER2-positive breast cancer.

This activity is designed to be interactive and fast-paced, allowing you to test your knowledge and practice through a series of multiple choice questions. The activity includes case vignettes, an opportunity to compare yourself to your peers, and to learn what the expert has to say about treatment approaches in HER2-positive breast cancer.

References:

  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. 2017. CA Cancer J Clin. 2017;67(1):7-30.
  2. Santa-Maria CA, Nye L, Mutonga MB, Jain S, Gradishar WJ. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? Oncology (Williston Park). 2016;30(2):148-155.

Faculty

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Hope S. Rugo, MD, has affiliations with Eisai, Genentech, Lilly, Macrogenics, Merck, Novartis, OBI Pharma, Pfizer, and Plexxikon – all funding to UC Regents only (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC
Carrie Noriega, MD, has no affiliations with commercial interests to disclose.
Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine

The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. 

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.

Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, registered nurses, and physician assistants are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, registered nurses, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Technical Support

For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
0.25 CME
University of Nebraska Medical Center
Podium to Practice: Updates from San Antonio in the Treatment of Breast Cancer – Focus on HR+/HER2- Disease

Podium to Practice: Updates from San Antonio in the Treatment of Breast Cancer – Focus on HR+/HER2- Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: December 29, 2017
Expires: December 29, 2018
15 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend

  

Target Audience

The target audience for this activity is community and academic medical oncologists, advanced practitioners, and other clinicians who treat patients with breast cancer.

Learning Objectives

  • Review the current therapeutic landscape of HR+/HER2- breast cancer
  • Evaluate recently released clinical trial data of current and emerging agents undergoing examination in patients with HR+/HER2- breast cancer
  • Discuss how recently released clinical trial data can be integrated into the treatment armamentarium
  • Develop strategies for the individualized treatment of patients with breast cancer based on efficacy and safety data, as well as patient and disease characteristics

Activity Description

Podium to Practice is an interview involving 2 world renowned experts actively engaged in treatment of patients with breast cancer. They provide expert summary and interpretation of data presented during the 2017 breast cancer conference in San Antonio, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

Due to the volume of research in the treatment of breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Clinicians need expert guidance to assess the benefits of agents for HR+/HER2- breast cancer, to use existing and novel ones safely and effectively, and to plan for optimal integration of new ones as they become available.

Agenda

  • Introduction
  • Current approaches to the care of HR+/HER2- advanced breast cancer
  • MONALESSA-7, Abstract GS2-05
  • neoMONARCH, Abstract PD5-01
  • ABCSG-16, Abstract GS3-01
  • TEXT and SOFT, Abstracts GS4-02 and GS4-03
  • Points to Ponder

Moderator

Mathew N. Beshara, MD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

No financial relationships to disclose


Faculty

Sara A. Hurvitz, MD
Associate Professor, Division of Hematology-Oncology, Department of Medicine
David Geffen School of Medicine at UCLA
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Medical Director, Clinical Research
UCLA Jonsson Comprehensive Cancer Center
Director, Breast Oncology Program
Division of Hematology-Oncology, UCLA
Los Angeles, California

Grants/Research Support: Amgen Inc., Bayer Healthcare Pharmaceuticals LLC, BioMarin, Boehringer Ingelheim, Cascadian Therapeutics, Dignitana AB, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline plc, Merrimack, Medivation, Inc., Novartis, OBI Pharma, Inc., Pfizer Inc, Puma Biotechnology, Inc, Seattle Genetics, Inc.

Other: Bayer Healthcare Pharmaceuticals LLC, Eli Lilly and Company, Novartis, OBI Pharma, Inc.


Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Grants/Research Support: Eisai Co., Ltd, Eli Lilly and Company, Genentech/Roche, OBI Pharma, Inc., Pfizer Inc, Plexxikon, Merck & Co., Inc, Novartis


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation. Participants who complete the educational activity, pre-/post-test and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME / CE
AKH Inc., Advancing Knowledge in Healthcare
A Systematic, Patient-Centered Approach to Managing Metastatic Gastric or GEJ Adenocarcinoma

A Systematic, Patient-Centered Approach to Managing Metastatic Gastric or GEJ Adenocarcinoma

Start

Activity Details

Free CME/CE
1.0 AMA PRA Category 1 Credit
1.0 ANCC Contact Hour
Released: December 21, 2017
Expires: December 21, 2018
1 hour to complete

Media

Internet

Target Audience

Oncology clinicians including physicians, nurses, and PAs

Learning Objectives

  1. Summarize the pathogenesis and molecular pathways involved in the development and progression of gastric cancer
  2. Evaluate the safety, efficacy, and quality of data for available and emerging targeted therapies for locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma
  3. Individualize and optimize treatment with sequencing and management of treatment-related adverse events for locally advanced or metastatic gastric and GEJ adenocarcinoma
  4. Engage patients with locally advanced or metastatic gastric and GEJ adenocarcinoma in their care by implementing effective shared decision making (SDM) strategies

Faculty

Jaffer A. Ajani, MD
Professor of Medicine, Department of Gastrointestinal Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure Declaration

It is the policy of RMEI Medical Education, LLC and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH Inc. prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. planners and reviewers have no relevant financial relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Jaffer A. Ajani, MD, has affiliations with Bristol-Myers Squibb, Celgene, Genentech, Insys, Lilly, and Medscape (Consulting Fees), and Bristol-Myers Squibb and Delta-Fly (Contracted Research). 

RMEI Medical Education, LLC

  • Tania Dickson, MD, has no affiliations with commercial interests to disclose.
  • Mindy Tanzola, PhD, has no affiliations with commercial interests to disclose.
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Jessica Hatch has no affiliations with commercial interests to disclose.

AKH Inc. Staff and Planners
Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner: has no affiliations with commercial interests to disclose.
Patricia Brignoni, Sr. Project Manager: has no affiliations with commercial interests to disclose.

Continuing Education Information

CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Nurses
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is awarded 1.0 Contact Hour.

Jointly provided by RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare.

How to Receive Credit

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through the participant's misunderstanding of the content.

Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions about the Activity

If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

0.25 CME / CNE / CPE
Rush University Medical Center
Updates from the National Multiple Myeloma Rounds Series: Focus on Amyloidosis

Updates from the National Multiple Myeloma Rounds Series: Focus on Amyloidosis

Start

Faculty

Agne Paner, MD (CME Course Director)
Assistant Professor of Medicine at Rush University Medical Center,
Division of Hematology/Oncology and Stem Cell Transplant
Director, Coleman Foundation Comprehensive Multiple Myeloma Clinic
Rush University Medical Center
Chicago, IL

Agne Paner, MD has disclosed having the following financial arrangements or affiliations with the commercial interests listed below whose products or services may be mentioned in this activity.
Advisory Board: Takeda Oncology
Member, Speakers’ Bureau: Celgene, Onyx/Amgen
Consultant: Takeda Oncology


Kimberly Lynch
Planner/Manager
PleXus Communications
Kim Lynch has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.

Michaela Ryan, PhD
PleXus Communications
Michaela Ryan, PhD has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.

Accredited By

Rush University Medical Center

Co-provided By

Activity Details

Free CME/CNE/CPE
0.25 AMA PRA Category 1 Credit
0.25 Contact Hour(s)
Released: December 21, 2017
Expires: December 20, 2018
20 minutes to complete

Goals (Purpose) of Program

To provide learners with a greater ability to formulate optimal evidence based strategies for the individualized treatment of their patients with multiple myeloma.

Learning Objectives

At the completion of this module, participants should be able to:

  • Apply current diagnostic approaches to accurately identify the type of amyloidosis, measure the extent of organ involvement, and determine the patient’s prognosis
  • Prescribe the optimal treatment plan for patients with amyloidosis
  • Identify patients with amyloidosis who would benefit from autologous stem cell transplant

Target Audience

This activity is designed to meet the needs of healthcare professionals involved in the treatment of patients with multiple myeloma.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours.

Rush University Medical Center designates this knowledge-based CPE activity 0622-0000-17-056-H01-P for 0.25 contact hours for pharmacists.

This activity is being presented without bias and with commercial support.

Requirements for Successful Completion

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 2 out of 3 or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from AbbVie, Amgen, Celgene Corporation, Incyte Corporation, Janssen Biotech, Inc., and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CNE / CPE
Rush University Medical Center
Updates from the National Multiple Myeloma Rounds Series: Focus on Relapsed Multiple Myeloma

Updates from the National Multiple Myeloma Rounds Series: Focus on Relapsed Multiple Myeloma

Start

Faculty

Agne Paner, MD (CME Course Director)
Assistant Professor of Medicine at Rush University Medical Center,
Division of Hematology/Oncology and Stem Cell Transplant
Director, Coleman Foundation Comprehensive Multiple Myeloma Clinic
Rush University Medical Center
Chicago, IL

Agne Paner, MD has disclosed having the following financial arrangements or affiliations with the commercial interests listed below whose products or services may be mentioned in this activity.
Advisory Board: Takeda Oncology
Member, Speakers’ Bureau: Celgene, Onyx/Amgen
Consultant: Takeda Oncology


Kimberly Lynch
Planner/Manager
PleXus Communications
Kim Lynch has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.

Michaela Ryan, PhD
PleXus Communications
Michaela Ryan, PhD has reported having no financial arrangements or affiliations with any commercial interest(s) whose products or services maybe mentioned in this activity.

Accredited By

Rush University Medical Center

Co-provided By

Activity Details

Free CME/CNE/CPE
0.25 AMA PRA Category 1 Credit
0.25 Contact Hour(s)
Released: December 21, 2017
Expires: December 20, 2018
20 minutes to complete

Goals (Purpose) of Program

To provide learners with a greater ability to formulate optimal evidence based strategies for the individualized treatment of their patients with multiple myeloma.

Learning Objectives

At the completion of this module, participants should be able to:

  • Choose among treatment options available for patients with early relapsed multiple myeloma
  • Identify which patients could benefit from salvage transplant in relapsed multiple myeloma
  • Optimize treatment plan for patient with relapsed refractory multiple myeloma
  • Manage disease and treatment complications in patients with relapsed multiple myeloma

Target Audience

This activity is designed to meet the needs of healthcare professionals involved in the treatment of patients with multiple myeloma.

Conflict of Interest Policy/Disclosure Statement

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Rush University Medical Center designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC Credit Designation – Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours.

Rush University Medical Center designates this knowledge-based CPE activity 0622-0000-17-058-H01-P for 0.25 contact hours for pharmacists.

This activity is being presented without bias and with commercial support.

Requirements for Successful Completion

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Instructions for Receiving Credit

Participants must complete and submit the online CE evaluation form at the conclusion of the activity and achieve a passing score of 2 out of 3 or better. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from AbbVie, Amgen, Celgene Corporation, Incyte Corporation, Janssen Biotech, Inc., and Merck.

Disclaimer Statement/Disclosure of Unlabeled Use

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Rush University, PleXus Communications, and/or the commercial supporters. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Rush University, PleXus Communications and/or the commercial supporters. Rush University’s ANCC accreditation status does not imply endorsement by Rush or ANCC of any commercial products displayed in conjunction with this activity. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Contact Information for Questions about the Activity

Info@plexuscomm.com
866-607-4333

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME / CNE / CPE
AXIS
FAQs on Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer

FAQs on Staying Up to Date on the Treatment of Advanced HR-Positive, HER2-Negative Breast Cancer

Start

Activity Details

Free CME/CPE/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hours
Released: November 21, 2017
Expires: November 20, 2018
30 minutes to complete

Provided By

This activity is provided by  

Target Audience

This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who manage breast cancer.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Summarize efficacy data for CDK 4/6 inhibitors in the setting of advanced HR-positive, HER2-negative breast cancer
  • Identify differences in adverse events among the available CDK 4/6 inhibitors
  • Analyze available data to determine appropriate individualized treatment selection for patients with advanced HR-positive, HER2-negative breast cancer

Activity Description

The goal for this activity is to provide an expert perspective on frequently asked questions pertaining to the treatment of advanced HR-positive, HER2-negative breast cancer to help clinicians gain an enhanced understanding of this disease to offer the best possible treatment choices to their patients.

Breast cancers that are hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative represent the most common subtype of breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies. Endocrine therapy is currently the cornerstone of treatment for advanced HR-positive breast cancer. However, not all patients respond to first-line endocrine therapy, and those that do respond eventually experience disease relapse. Resistance to endocrine therapy is common, and complete disease resistance to additional endocrine therapy eventually develops in patients with HR-positive metastatic breast cancer (MBC). The 5-year and 10-year survival rates for MBC are 26% and 5% to 10%, respectively. Significant therapeutic advances in this area include the development of agents that target critical pathways involved in the development of resistance to endocrine therapy. These include mechanistic target of rapamycin (mTOR) inhibitors and cyclin-dependent kinase (CDK) 4/6 inhibitors.

This activity will focus on endocrine therapy, CDK 4/6 inhibitors, and treatment selection/sequencing.

Author

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Hematology-Oncology
Associate Director, Translational Research
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, Pennsylvania


Co-Author

Aju Mathew, MD, MPhil, FACP
Assistant Professor of Medicine
University of Kentucky
Lexington, Kentucky


Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The author, Adam M. Brufsky, MD, PhD reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:  Received consulting fees from Lilly USA, Novartis  Pharmaceuticals Corp, Pfizer, Inc.

The co-author Aju Mathew, MD, MPhil, FACP has no real or apparent financial relationships to report.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko; Laura Healy; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Stephanie Sutphin, PharmD, reports a financial interest/relationship or affiliation in the form of Advisory board: Seattle Genetics and Amgen Biosimilars.

Continuing Education Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 0.5 contact hour of continuing pharmacy education credit. UAN 0592-0000-17-046-H01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Disclosure of Unlabeled Use

This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at info@axismeded.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages